PRINCETON - Global law firm Reed Smith has advised U.S biotech Sanaria on a venture financing deal with the EU Malaria Fund. Under the terms of the deal Sanaria will receive a venture loan of nearly 13 million Euros for the development of two malaria vaccines, a malaria therapeutic and an oral COVID-19 vaccine.

Related Professionals: Nanette W. Mantell Nicholas J. Valvanis René Lochmann Ivan Zlatanov

Sanaria is headquartered in Rockville, Maryland (USA) and is a world leader in the research and development of malaria vaccines and other malaria research products intended to combat malaria in individuals and in combination with other malaria control measures with a goal of halting the transmission of malaria and ultimately realizing its elimination. Recently, the company also started to develop vaccines against COVID-19.

Sanaria and the EU Malaria Fund are dedicated to the same primary goal. The EU Malaria Fund’s mission is to support the control and potential eradication of malaria. The EU malaria Fund is managed by Investitionsbank Berlin and works with a group of partners including, the European Investment Bank, the Bill & Melinda Gates Foundation, the WHO, Novartis and other international and private European stakeholders.

The Reed Smith team from the U.S. and Munich was led by Nan Mantell and Nicholas Valvanis in the firm’s Princeton office with assistance from Rene Lochmann and Ivan Zlatanov in the firm’s Munich office.

Reed Smith has been counsel to Sanaria for more than a decade.